LONDON – The National Health Service (NHS) in England is to stop paying for 16 high-cost oncology products in a move that has offended clinicians, patients groups and companies, and once again has drawn attention to the inequity of having a separate mechanism to pay for cancer treatments, under which they are not subject to the same value assessments as drugs for other indications.